Farmácia/Notícias da Indústria

Diretriz de consenso | Manejo pré-operatório de medicamentos cardiovasculares.

6 Set, 2022 | 13:16h

Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Conteúdos relacionados:

Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Neurologic Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Psychiatric Diseases: Society for Perioperative Assessment and Quality Improvement Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Gastrointestinal and Pulmonary Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Opioid and Nonopioid Analgesics: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Surgical Patients Using Dietary Supplements – Mayo Clinic Proceedings

Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings

Preoperative Cardiac Risk Assessment – Mayo Clinic Proceedings

Preoperative Evaluation Before Noncardiac Surgery – Mayo Clinic Proceedings

Perioperative Cardiac Risk Reduction in Noncardiac Surgery – Mayo Clinic Proceedings

Examining Risk: A Systematic Review of Perioperative Cardiac Risk Prediction Indices – Mayo Clinic Proceedings

Perioperative Venous Thromboembolism Prophylaxis – Mayo Clinic Proceedings

 

---

FDA autoriza doses de reforço atualizadas para novas variantes do COVID com vacinas da Moderna e da Pfizer.

6 Set, 2022 | 13:11h

FDA authorizes updated COVID boosters from Moderna and Pfizer – CIDRAP

Comunicado de imprensa do FDA: Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose – U.S. Food & Drug Administration

 

---

Revisão | Prevenção e tratamento de náusea e vômito durante a terapia oncológica.

6 Set, 2022 | 12:51h

The Prevention and Treatment of Nausea and Vomiting During Tumor Therapy – Deutsches Ärzteblatt International

Conteúdos relacionados:

SEOM clinical guideline emesis (2021) – Clinical and Translational Oncology

M-A: Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy.

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes – Drugs & Aging (se o acesso a este link for pago, tente este)

 

---

Revisão de escopo de estudos randomizados sobre descontinuação de medicamentos em idosos.

29 Ago, 2022 | 17:42h

Scoping Review of Randomized Trials With Discontinuation of Medicines in Older Adults – JAMDA

 

---

Estudo de coorte retrospectiva | Uso de nirmatrelvir e desfechos de Covid-19 grave durante o aumento da variante Ômicron.

29 Ago, 2022 | 17:16h

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge – New England Journal of Medicine

 

Comentário no Twitter

During the clinical rollout of nirmatrelvir in Israel in early 2022, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen among patients at highest risk for Covid-19 progression, such as those 65+. https://t.co/O6CxzDdIfH pic.twitter.com/ccCaCCh15i

— NEJM (@NEJM) August 24, 2022

---

Declaração de recomendação USPSTF | Uso de estatinas para prevenção primária de doença cardiovascular em adultos.

29 Ago, 2022 | 16:49h

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement – JAMA

Editoriais:

Statins for Primary Cardiovascular Disease Prevention: Time to Curb Our Enthusiasm – JAMA Internal Medicine

Statins and Primary Atherosclerotic Cardiovascular Disease Prevention—What We Know, Where We Need to Go, and Why Are We Not There Already? – JAMA Network Open

Relatório de evidência: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Entrevista com o autor: USPSTF Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults – JAMA

Página do paciente: Statins for the Prevention of Cardiovascular Disease – JAMA

Comentário: Latest statins guidance keeps more conservative approach to preventing first stroke or heart attack – CNN

 

---

Revisão sistemática | Carga anticolinérgica para predição de declínio cognitivo ou sintomas neuropsiquiátricos em idosos com comprometimento cognitivo leve ou demência.

29 Ago, 2022 | 16:33h

Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia – Cochrane Library

Resumo: The impact of cumulative medications with anticholinergic effects on future adverse clinical outcomes in people with dementia – Cochrane Library

Conteúdos relacionados:

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

Commonly-prescribed drugs and dementia: should we be worried? – Evidently Cochrane

Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome – Cochrane Library

Anticholinergic drugs and dementia: time for transparency in the face of uncertainty – Cochrane Library

Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study – JAMA Internal Medicine

How well do you know your anticholinergic (antimuscarinic) drugs? – Therapeutics Initiative

Anticholinergic drugs and risk of dementia: case-control study – The BMJ

 

---

Diretriz OMS | Determinantes comportamentais e sociais da vacinação: ferramentas e diretriz prática para alcançar um alto nível de entendimento.

23 Ago, 2022 | 17:07h

Behavioural and social drivers of vaccination: tools and practical guidance for achieving high uptake – World Health Organization

 

---

Estudo randomizado | Metformina, ivermectina e fluvoxamina não são benéficas para pacientes ambulatoriais obesos com Covid-19.

22 Ago, 2022 | 16:44h

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19 – New England Journal of Medicine

Editorial: Time to Stop Using Ineffective Covid-19 Drugs – New England Journal of Medicine

 

Comentário no Twitter

In this trial involving overweight or obese outpatients with Covid-19, investigators found that none of three repurposed drugs (metformin, ivermectin, and fluvoxamine) reduced the risk of serious disease. https://t.co/8sd6R7CDK6 pic.twitter.com/bPZ6zeuZSA

— NEJM (@NEJM) August 17, 2022

 

---

Análise agrupada de doença pulmonar intersticial relacionada a medicamentos e/ou pneumonite em 9 estudos de monoterapia com trastuzumabe deruxtecano.

22 Ago, 2022 | 16:34h

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies – ESMO Open

Comentários:

Prompt recognition and treatment found effective for lung disease in patients who received new drug for advanced cancer – The Mount Sinai Health System

Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News

Conteúdo relacionado: Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review – Drugs

 

---